Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?
Current Oncology · 2023
DOI: 10.3390/curroncol30010090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Manon Lefebvre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, France. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Uterine Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (p = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (p = 0.056). In contrast, OS (p = 0.97) and PFS (p = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, France.
- Methodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France.
- Department of Medical Oncology, Centre Oscar Lambret, 59000 Lille, France.
- Academic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France.
- Univ. Lille, Inserm, CHU Lille, U1192-Protéomique Réponse Inflammatoire Spectrométrie de Masse-PRISM, 59000 Lille, France.
ORCID-Profile: Marie Cécile Le Deley, Eric Leblanc, Delphine Hudry
Zitieren
APA
Lefebvre, M., Duchatelet, M., El Hajj, H., De Courrèges, A., Wallet, J., Bellier, C., Le Tinier, F., Le Deley, M. C., Martinez Gomez, C., Leblanc, E., Narducci, F., & Hudry, D. (2023). Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?. Current Oncology. https://doi.org/10.3390/curroncol30010090
Vancouver
Lefebvre M, Duchatelet M, El Hajj H, De Courrèges A, Wallet J, Bellier C, et al. Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?. Current Oncology. 2023. doi:10.3390/curroncol30010090
BibTeX
@article{Lefebvre2023,
author = {Lefebvre, Manon and Duchatelet, Mathilde and El Hajj, Houssein and De Courrèges, Antoine and Wallet, Jennifer and Bellier, Charlotte and Le Tinier, Florence and Le Deley, Marie Cécile and Martinez Gomez, Carlos and Leblanc, Eric and Narducci, Fabrice and Hudry, Delphine},
title = {Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30010090}
}
EUVIMED